Article Information
History
- April 2, 2021.
Article Versions
- Version 1 (January 29, 2021 - 06:42).
- Version 2 (January 29, 2021 - 15:18).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Pegah Farrokhi1,
- Alireza Sadeghi2,
- Mehran sharifi2,
- Payam Dadvand3,
- Rachel Riechelmann4 and
- Azadeh Moghaddas1,*
- 1Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
- 2Department of Internal Medicine-Hematology Section, Isfahan University of Medical Sciences, Isfahan, Iran
- 3Barcelona Institute for Global Health, Barcelona, Spain
- 4Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil
- ↵*Corresponding author:
Dr. Azadeh Moghaddas, Assistant Professor of Clinical Pharmacy, Isfahan University of Medical Sciences, E-mail: moghaddas{at}pharm.mui.ac.ir, Tel: +983137927074
Posted April 02, 2021.
Efficacy and Safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as Perioperative Chemotherapy Treatments for Resectable Gastric Cancer Patients
